Options for generating polycystic ovary syndrome based on experimental findings in animal models

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine pathology that affects 8–14% of women of reproductive age. The leading signs of the disease are hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Over the past decades, a variety of animal models have been developed to study the etiology and pathogenesis of PCOS, including chemical, hormonal, and genetic interventions. However, a large number of experimental techniques differ even in the framework of a single model. In this review article, we summarized PCOS animal models using both direct hormonal effects and indirect methods.

Keywords

polycystic ovary syndrome / animal models / ovaries / pathogenesis

References

[1] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. https://doi.org/10.1016/j.fertnstert.2003.10.004.

[2] Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. 2008;14(5):539. Hum Reprod Update. 2008;14(4):367-378. https://doi.org/10.1093/humupd/dmn015.

[3] Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-231. https://doi.org/10.1038/nrendo.2010.217.

[4] Abbott DH, Dumesic DA, Eisner JR, et al. Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab. 1998;9(2):62-67. https://doi.org/10.1016/s1043-2760(98)00019-8.

[5] Wu XY, Li ZL, Wu CY, et al. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Endocr J. 2010;57(3):201-209. https://doi.org/10.1507/endocrj.k09e-205.

[6] Yan X, Dai X, Wang J, et al. Prenatal androgen excess programs metabolic derangements in pubertal female rats. J Endocrinol. 2013;217(1):119-129. https://doi.org/10.1530/JOE-12-0577.

[7] Caldwell AS, Middleton LJ, Jimenez M, et al. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology. 2014;155(8):3146-3159. https://doi.org/10.1210/en.2014-1196.

[8] Ota H, Fukushima M, Maki M. Endocrinological and histological aspects of the process of polycystic ovary formation in the rat treated with testosterone propionate. Tohoku J Exp Med. 1983;140(2):121-131. https://doi.org/10.1620/tjem.140.121.

[9] Tyndall V, Broyde M, Sharpe R, et al. Effect of androgen treatment during foetal and/or neonatal life on ovarian function in prepubertal and adult rats. Reproduction. 2012;143(1):21-33. https://doi.org/10.1530/REP-11-0239.

[10] Cruz G, Barra R, González D, et al. Temporal window in which exposure to estradiol permanently modifies ovarian function causing polycystic ovary morphology in rats. Fertil Steril. 2012;98(5):1283-1290. https://doi.org/10.1016/ j.fertnstert.2012.07.1060.

[11] Fernández M, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol A and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environ Health Perspect. 2010;118(9):1217-1222. https://doi.org/10.1289/ehp.0901257.

[12] Schulster A, Farookhi R, Brawer JR. Polycystic ovarian condition in estradiol valerate-treated rats: Spontaneous changes in characteristic endocrine features. Biol Reprod. 1984;31(3):587-593. https://doi.org/10.1095/biolreprod31.3.587.

[13] Brawer JR, Munoz M, Farookhi R. Development of the polycystic ovarian condition (PCO) in the estradiol valerate-treated rat. Biol Reprod. 1986;35(3):647-655. https://doi.org/10.1095/biolreprod35.3.647.

[14] Hemmings R, Farookhi R, Brawer JR. Pituitary and ovarian responses to luteinizing hormone releasing hormone in a rat with polycystic ovaries. Biol Reprod. 1983;29(1):239-248. https://doi.org/10.1095/biolreprod29.1.239.

[15] Quandt LM, Hutz RJ. Induction by estradiol-17 beta of polycystic ovaries in the guinea pig. Biol Reprod. 1993;48(5):1088-1094. https://doi.org/10.1095/biolreprod48.5.1088.

[16] Risma KA, Hirshfield AN, Nilson JH. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology. 1997;138(8):3540-3547. https://doi.org/10.1210/endo.138.8.5313.

[17] Devin JK, Johnson JE, Eren M, et al. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol. 2007;39(1):9-16. https://doi.org/10.1677/JME-06-0057.

[18] Shi D, Dyck MK, Uwiera RR, et al. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. Endocrinology. 2009;150(9):4425-4436. https://doi.org/10.1210/en.2008-1612.

[19] Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: A new model for cystic ovarian disease. Arch Med Res. 2004;35(2):103-108. https://doi.org/10.1016/j.arcmed.2003.10.005.

[20] Li C, Chen L, Zhao Y, et al. Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model. Gene. 2017;598:20-26. https://doi.org/10.1016/j.gene.2016. 10.033.

[21] Bernuci MP, Szawka RE, Helena CV, et al. Locus coeruleus mediates cold stress-induced polycystic ovary in rats. Endocrinology. 2008;149(6):2907-2916. https://doi.org/10.1210/en.2007-1254.

[22] Baldissera SF, Motta LD, Almeida MC, Antunes-Rodrigues J. Proposal of an experimental model for the study of polycystic ovaries. Braz J Med Biol Res. 1991;24(7):747-751.

[23] Kang X, Jia L, Shen X. Manifestation of hyperandrogenism in the continuous light exposure-induced PCOS rat model. Biomed Res Int. 2015;2015:943694. https://doi.org/10.1155/2015/943694.

[24] Lagace DC, Nachtigal MW. Valproic acid fails to induce polycystic ovary syndrome in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):587-594. https://doi.org/10.1016/S0278-5846(03)00045-9.

[25] Tata B, Mimouni NE, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24(6):834-846. https://doi.org/10.1038/s41591-018-0035-5.

[26] Volk KM, Pogrebna VV, Roberts JA, et al. High-Fat, High-Sugar diet disrupts the preovulatory hormone surge and induces cystic ovaries in cycling female rats. J Endocr Soc. 2017;1(12):1488-1505. https://doi.org/10.1210/js. 2017-00305.

[27] Roberts JS, Perets RA, Sarfert KS, et al. High-fat high-sugar diet induces polycystic ovary syndrome in a rodent model. Biol Reprod. 2017;96(3):551-562. https://doi.org/10.1095/biolreprod.116.142786.

[28] Maliqueo M, Sun M, Johansson J, et al. Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology. 2013;154(1):434-445. https://doi.org/10.1210/en.2012-1693.

[29] Ansel L, Bolborea M, Bentsen AH, et al. Differential regulation of kiss1 expression by melatonin and gonadal hormones in male and female Syrian hamsters. J Biol Rhythms. 2010;25(2):81-91. https://doi.org/10.1177/0748 730410361918.

[30] Vanecek J. Inhibitory effect of melatonin on GnRH-induced LH release. Rev Reprod. 1999;4(2):67-72. https://doi.org/10.1530/ror.0.0040067.

RIGHTS & PERMISSIONS

Yarmolinskaya M.I., Abashova E.I., Bulgakova O.L.